[11C]HSP990 PET dosimetry for Parkinson's (NCT07380204)
Measure heat shock protein levels
- Trial ID
- NCT07380204
- Official Title
- In Vivo Quantification of Hsp90 in the Human Brain in Healthy Aging and Neurodegeneration Using the Novel PET Radioligand [11C]HSP990
- Goal
- Measure heat shock protein levels
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study Type
- INTERVENTIONAL
- Enrollment
- 48 participants
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
Summary For Families
The goal is to see if a special PET scan tracer can measure levels of Hsp90, a protein that helps other proteins fold correctly and keeps brain cells stable, because Parkinson's and related diseases involve misfolded proteins that clump together. The approach is to give a very small radiolabeled tracer and image the brain with positron emission tomography to map Hsp90 in living people; the tracer has shown safe, favorable results in animals and the scans could help test future drugs that target Hsp90. The study is enrolling healthy adults in several age groups (roughly 18 to 70), people with Parkinson's (about 45 to 85 with a confirmed diagnosis, mild-to-moderate disease, and a prior abnormal dopamine-transporter scan), people with probable Alzheimer's (about 45 to 85 with lower cognitive test scores and biomarker evidence from an amyloid scan or spinal fluid test), and people with amyotrophic lateral sclerosis (about 20 to 85) who can give written informed consent.
Locations
- UZ Leuven, Leuven, Vlaam-Brabant, Belgium
Frequently Asked Questions
- What is this trial testing?
- This trial is studying [11C]HSP990 PET dosimetry. The goal is to see if a special PET scan tracer can measure levels of Hsp90, a protein that helps other proteins fold correctly and keeps brain cells stable, because Parkinson's and related diseases involve misfolded proteins that clump together. The approach is to give a very small radiolabeled tracer and image the brain with positron emission tomography to map Hsp90 in living people; the tracer has shown safe, favorable results in animals and the scans could help test future drugs that target Hsp90. The study is enrolling healthy adults in several age groups (roughly 18 to 70), people with Parkinson's (about 45 to 85 with a confirmed diagnosis, mild-to-moderate disease, and a prior abnormal dopamine-transporter scan), people with probable Alzheimer's (about 45 to 85 with lower cognitive test scores and biomarker evidence from an amyloid scan or spinal fluid test), and people with amyotrophic lateral sclerosis (about 20 to 85) who can give written informed consent.
- Who can participate?
- Participants must be between 18 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 3 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.
- How many visits does this trial involve?
- Part 1: three volunteers will have a whole-body PET/CT scan lasting 120 minutes; Part 2: five volunteers will have a PET/CT brain scan lasting 120 minutes and all five will have a retest scan within one week; Part 3: 30 patients and 10 healthy controls will have a dynamic PET/CT brain scan.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Blood draw (minimally invasive); PET scan (minimally invasive). Confirm the full schedule with the study coordinator.